{"id":"W2972122997","doi":"10.1016/j.clbc.2019.08.009","title":"Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2","year":2019,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Daiichi Sankyo Europe; Genentech; Daiichi Sankyo Company; Plexxikon; PharmaMar; Eisai; MacroGenics; Amgen; Nippon Kayaku; Astellas Pharma; Mylan; Genomic Health; Novartis Pharma; Novartis; Pfizer; Ontario Brain Institute; Merck; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Palbociclib; Letrozole; Medicine; Breast cancer; Internal medicine; Oncology; Placebo; Metastatic breast cancer; Estrogen receptor; Progression-free survival; Odds ratio; Population; Adverse effect; Cancer; Gynecology; Tamoxifen; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001671928,0.0004051327,0.0009177466,0.0003307507,0.0001658598,0.0004953173,0.0003913935,0.0003985731,0.001300215],"category_scores_gemma":[0.001463961,0.0002133602,0.001304739,0.0002711381,0.0003808351,0.0004332423,0.0002792666,0.0009807821,0.000145912],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000462958,"about_ca_system_score_gemma":0.0004757913,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003687958,"about_ca_topic_score_gemma":0.0009976836,"domain_scores_codex":[0.99942,0.0002885198,0.00004247109,0.00009149858,0.00007877868,0.00007881595],"domain_scores_gemma":[0.9988869,0.0004513726,0.0003703221,0.00005726275,0.000037396,0.0001967528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5920227,0.004073823,0.3327238,0.0006475527,0.005167028,0.0002395063,0.0001562151,0.001905042,0.007318922,0.0001428292,0.0009285109,0.05467406],"study_design_scores_gemma":[0.06783576,0.1373882,0.7786402,0.00007595403,0.005837768,0.0006339829,0.0001381757,0.003926099,0.002846269,0.0004716769,0.00215223,0.00005359958],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984831,0.0009678196,0.00006119176,0.00005460616,0.00001109211,0.00003937766,0.0001553996,0.000003622781,0.0002238048],"genre_scores_gemma":[0.9990694,0.0002760213,0.00006455959,0.0000675674,0.00003391895,0.00004807228,0.0002893046,0.000001321638,0.0001498265],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001671928,"threshold_uncertainty_score":0.008842111,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02003432836318951,"score_gpt":0.3391463333567022,"score_spread":0.3191120049935127,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}